Brought to you by 
Roche, Syrrx develop cancer, diabetes compounds
18 May 2004
Executive Summary
Under terms of a three-year deal, F. Hoffmann-La Roche and Syrrx agreed to discover and develop cancer and Type II diabetes drug candidates that act on HDAC (histone deacetylase), a cancer target that regulates gene transcription, and 11-beta HSD-1, a metabolic target that reduces cortisol production. The programs are in the preclinical development stage.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche, Syrrx develop cancer, diabetes compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice